• 10-year Reagent and Consumables Supply Agreement with Hvidovre Hospital in Denmark
• Contract for testing of 28,000 samples in the first year, with 3% estimated annual growth
• Adoption of Genetic Signatures' EasyScreen™ Pan-Enteric assay based on 3base® multiplex technology

Genetic Signatures Limited (ASX: GSS) has signed agreements for the supply of Equipment, Reagents and Consumables for Gastrointestinal Screening at Hvidovre Hospital in Denmark. The Reagent and Consumables Supply Agreement has a ten-year term, extendable for up to two 12-month periods, while the Equipment Supply Agreement has no fixed term. Hvidovre is one of Denmark's leading public hospitals, and the contract is for the testing of 28,000 samples in the first year, with a 3% estimated growth annually. Under the agreement, Hvidovre Hospital will adopt Genetic Signatures' EasyScreen™ Pan-Enteric assay, based on its proprietary 3base® multiplex technology, which detects a broad range of strains of 24 gastrointestinal pathogens in a single, fully automated workflow. The contract reflects growing international recognition of the clinical and operational advantages of the company's pan-enteric diagnostic approach, which consolidates what has traditionally required complex multi-test algorithms into a streamlined workflow, delivering material benefits across the laboratory and broader hospital environment, including reduced risk, improved infection-control, and shorter patient stay.

The Hvidovre Hospital tender is a critical milestone for Genetic Signatures' EMEA growth strategy and further validates the clinical and operational case for the company's EasyScreen™ Pan-Enteric solution in international markets. The contract, combined with the outcomes seen in the UK and other markets, demonstrates that the pan-enteric approach delivers measurable, real-world benefits for laboratories, clinicians, and patients, signaling growing momentum for broader adoption of the platform across Europe and globally.